Sevabertinib is a medicine used to treat a type of lung cancer that has a change in a gene called HER2. It is taken as a pill by mouth. It works by blocking the faulty HER2 signal that tells the cancer cells to grow.
Every report comes from a Lived member, sent anonymously.
Have you tried Hyrnuo (Sevabertinib) for Non-Small Cell Lung Cancer?
Sevabertinib, sold under the brand name Hyrnuo, is a targeted cancer medicine for adults with non-small cell lung cancer (NSCLC) that is locally advanced (grown into nearby tissues) or metastatic (spread to other parts of the body). It is approved only for the non-squamous type of NSCLC, and only when the tumor carries a specific change in the gene for HER2 (human epidermal growth factor receptor 2): an activating mutation in the part of HER2 that switches its growth signal on. That mutation has to be found by an FDA-authorized test, so this medicine depends on genetic testing of the cancer (often called biomarker testing) before it is considered. The approved use does not name a point in treatment, so it covers people starting their first cancer medicine as well as people treated before. The study behind it included three groups: people who had not yet had any cancer drug treatment, people who had already had chemotherapy or immunotherapy, and people whose cancer had grown after a HER2-targeted antibody drug conjugate (an infused medicine that carries chemotherapy to HER2-bearing cells). The FDA granted it accelerated approval. That means the decision rested on how often and for how long tumors shrank in a study, not yet on proof that it helps people live longer or better than other options. Continued approval may depend on a confirmatory trial.
HER2 is a protein on the surface of cells that relays signals telling them to grow and divide. In some lung cancers, a mutation leaves HER2 switched on all the time, so the signal keeps driving the cancer's growth even without the usual triggers. Sevabertinib is a kinase inhibitor, a type of drug that blocks the part of a protein that passes a signal into the cell. By blocking HER2 from inside the cell, it cuts off the growth signal the cancer has come to depend on, which can stop tumors from growing and often makes them shrink. It also blocks a closely related protein, EGFR (epidermal growth factor receptor). Sevabertinib controls the cancer rather than curing it, which is why treatment continues for as long as it keeps working.
Sevabertinib comes as tablets taken by mouth twice a day with food. The tablets should be swallowed whole, not cut, crushed or chewed. Treatment usually continues for as long as the cancer stays under control and side effects remain manageable. If a dose is missed, take it when remembered, as long as the next scheduled dose has not yet come; never take two doses together to catch up. If a dose is vomited, do not take another one; take the next dose at the usual time. Pausing treatment or lowering the dose is a routine way to manage side effects. In the main study, about half of people had treatment paused at some point and about a third had their dose lowered, while few stopped for good because of side effects. Dose changes should come from the oncology team, not be made on your own.
Diarrhea is the most common side effect, affecting nearly 9 in 10 people in studies. It usually begins within the first week and can become severe enough to cause dehydration and low levels of minerals such as potassium. Ask the care team before starting which anti-diarrhea medicine to keep at home, such as loperamide (Imodium). At the first loose stool or any increase in bowel movements, start that medicine, drink more fluids, and contact the care team right away. Other common effects include rash, dry or itchy skin, painful swelling or infection of the skin around the fingernails or toenails (paronychia), mouth sores, nausea, vomiting, poor appetite, weight loss and tiredness. Reporting these early gives the care team a chance to treat them or adjust the dose before they become hard to live with. A few less common effects are serious. Inflammation of the lungs (pneumonitis) affected a small number of people, but new or worsening shortness of breath, cough or fever should be reported to the care team right away; if pneumonitis is confirmed, sevabertinib is stopped permanently. Eye problems affected about 1 in 6 people, mostly mildly, but rarely damaged the surface of the eye, so any new or worsening eye symptoms or change in vision also needs a prompt call. The same goes for new or worsening heart symptoms, since the drug can weaken the heart's pumping and irregular heart rhythms were reported. Liver injury is more common and usually shows up first on routine blood tests, but yellowing of the skin or eyes or dark urine between tests should also be reported promptly.
Sevabertinib is broken down in the body by a liver enzyme called CYP3A. Medicines that strongly block this enzyme can raise sevabertinib levels and make side effects worse, so they are avoided, or the sevabertinib dose is lowered if one is truly needed. Medicines that speed the enzyme up can lower sevabertinib levels enough to make it less effective, and are avoided. Grapefruit and grapefruit juice should be avoided too. Sevabertinib can also raise the levels of some other medicines. Because many prescriptions, over-the-counter drugs and herbal supplements are involved, the oncologist and pharmacist should review everything you take, including anything another doctor starts later. Sevabertinib can harm a developing baby. Women who could become pregnant should use effective birth control during treatment and for 1 week after the last dose, and men taking it should do the same if their partner could become pregnant. Tell the care team right away about a known or suspected pregnancy. Breastfeeding is not recommended during treatment or for 1 week after the last dose. It has not been studied in people with significant heart disease or with reduced heart pumping before treatment, measured as a left ventricular ejection fraction (LVEF) below 50%. LVEF is the share of blood the heart's main pumping chamber pushes out with each beat, so a lower number means a weaker pump. A history of heart or lung disease is worth raising before starting.
Before the first dose, people have blood tests and a heart test, such as an ultrasound of the heart (echocardiogram), that measures LVEF, the pumping strength explained above. Liver blood tests are then repeated every two weeks during the first month and about monthly after that, because the drug can injure the liver. Blood levels of pancreatic enzymes (amylase and lipase) are checked regularly, since they rose in many people in studies, and the heart test is repeated at intervals. These results, along with how side effects are going, guide whether the dose stays the same, is paused or is lowered. Follow-up scans show whether the cancer is responding. In the main study, tumors shrank in about 3 in 4 people who had no earlier cancer drug treatment and in about 7 in 10 people who had prior treatment but no HER2-targeted drug. Among people whose cancer had grown after a HER2-targeted antibody drug conjugate, about 4 in 10 responded. In previously treated groups, responses typically lasted about 7 to 9 months, with some lasting over a year. These results come from a study without a comparison group, so it is not yet known how sevabertinib compares with other treatments for survival. Treatment continues while the cancer stays controlled and side effects are manageable. If the cancer grows, the care team will discuss what other options remain.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Hyrnuo (Sevabertinib), what you've noticed, or ask the community a question.